The Conversation (0)
Acasti Pharma was awarded a set of additional patents from the Taiwanese and Australian patent offices.
Acasti Pharma (NASDAQ:ACST, TSXV:ACST) received a set of additional patents from the Taiwanese and Australian patent offices.
As quoted in the press release:
The granted patents are valid until 2030 and relate to concentrated therapeutic krill oil-based phospholipid omega-3 compositions covering methods for treating or preventing disorders associated with cardiovascular diseases. These patents add to Acasti’s growing portfolio of issued patents in the United States, China, Mexico, Saudi Arabia, Panama, and South Africa. Patent applications with similar claim sets are being pursued in many other jurisdictions worldwide.
“The granting of these additional patents is another value enhancing milestone, further supporting possible licensing and partnership opportunities for CaPre,” said Pierre Lemieux, PhD, Acasti’s chief operating officer. “We are committed to building our global patent portfolio to ensure that we have long lasting and comprehensive protection, while also safeguarding valuable market expansion opportunities.”
Click here to read the full press release.
Source: www.marketwired.com
